Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39


Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy.

Wang J, Sun J, Liu LN, Flies DB, Nie X, Toki M, Zhang J, Song C, Zarr M, Zhou X, Han X, Archer KA, O'Neill T, Herbst RS, Boto AN, Sanmamed MF, Langermann S, Rimm DL, Chen L.

Nat Med. 2019 Apr;25(4):656-666. doi: 10.1038/s41591-019-0374-x. Epub 2019 Mar 4.


B7-H4 Modulates Regulatory CD4+ T Cell Induction and Function via Ligation of a Semaphorin 3a/Plexin A4/Neuropilin-1 Complex.

Podojil JR, Chiang MY, Ifergan I, Copeland R, Liu LN, Maloveste S, Langermann S, Liebenson D, Balabanov R, Chi H, Chen L, Vignali DAA, Miller SD.

J Immunol. 2018 Aug 1;201(3):897-907. doi: 10.4049/jimmunol.1700811. Epub 2018 Jun 13.


Vaccine-induced myeloid cell population dampens protective immunity to SIV.

Sui Y, Hogg A, Wang Y, Frey B, Yu H, Xia Z, Venzon D, McKinnon K, Smedley J, Gathuka M, Klinman D, Keele BF, Langermann S, Liu L, Franchini G, Berzofsky JA.

J Clin Invest. 2014 Jun;124(6):2538-49. doi: 10.1172/JCI73518. Epub 2014 May 16.


Immune targeting of PD-1(hi) expressing cells during and after antiretroviral therapy in SIV-infected rhesus macaques.

Vargas-Inchaustegui DA, Xiao P, Hogg AE, Demberg T, McKinnon K, Venzon D, Brocca-Cofano E, Dipasquale J, Lee EM, Hudacik L, Pal R, Sui Y, Berzofsky JA, Liu L, Langermann S, Robert-Guroff M.

Virology. 2013 Dec;447(1-2):274-84. doi: 10.1016/j.virol.2013.09.015. Epub 2013 Oct 9.


B7-H4Ig inhibits mouse and human T-cell function and treats EAE via IL-10/Treg-dependent mechanisms.

Podojil JR, Liu LN, Marshall SA, Chiang MY, Goings GE, Chen L, Langermann S, Miller SD.

J Autoimmun. 2013 Aug;44:71-81. doi: 10.1016/j.jaut.2013.04.001. Epub 2013 May 14.


B7-H4.Ig inhibits the development of type 1 diabetes by regulating Th17 cells in NOD mice.

Lee IF, Wang X, Hao J, Akhoundsadegh N, Chen L, Liu L, Langermann S, Ou D, Warnock GL.

Cell Immunol. 2013 Mar;282(1):1-8. doi: 10.1016/j.cellimm.2013.03.005. Epub 2013 Apr 4.


Early treatment of NOD mice with B7-H4 reduces the incidence of autoimmune diabetes.

Wang X, Hao J, Metzger DL, Mui A, Ao Z, Akhoundsadegh N, Langermann S, Liu L, Chen L, Ou D, Verchere CB, Warnock GL.

Diabetes. 2011 Dec;60(12):3246-55. doi: 10.2337/db11-0375. Epub 2011 Oct 7.


Substantially improved pharmacokinetics of recombinant human butyrylcholinesterase by fusion to human serum albumin.

Huang YJ, Lundy PM, Lazaris A, Huang Y, Baldassarre H, Wang B, Turcotte C, Côté M, Bellemare A, Bilodeau AS, Brouillard S, Touati M, Herskovits P, Bégin I, Neveu N, Brochu E, Pierson J, Hockley DK, Cerasoli DM, Lenz DE, Wilgus H, Karatzas CN, Langermann S.

BMC Biotechnol. 2008 May 16;8:50. doi: 10.1186/1472-6750-8-50.


Human recombinant butyrylcholinesterase purified from the milk of transgenic goats interacts with beta-amyloid fibrils and suppresses their formation in vitro.

Podoly E, Bruck T, Diamant S, Melamed-Book N, Weiss A, Huang Y, Livnah O, Langermann S, Wilgus H, Soreq H.

Neurodegener Dis. 2008;5(3-4):232-6. doi: 10.1159/000113711. Epub 2008 Mar 6.


Recombinant human butyrylcholinesterase from milk of transgenic animals to protect against organophosphate poisoning.

Huang YJ, Huang Y, Baldassarre H, Wang B, Lazaris A, Leduc M, Bilodeau AS, Bellemare A, Côté M, Herskovits P, Touati M, Turcotte C, Valeanu L, Lemée N, Wilgus H, Bégin I, Bhatia B, Rao K, Neveu N, Brochu E, Pierson J, Hockley DK, Cerasoli DM, Lenz DE, Karatzas CN, Langermann S.

Proc Natl Acad Sci U S A. 2007 Aug 21;104(34):13603-8. Epub 2007 Jul 27.


Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin.

Bouckaert J, Berglund J, Schembri M, De Genst E, Cools L, Wuhrer M, Hung CS, Pinkner J, Slättegård R, Zavialov A, Choudhury D, Langermann S, Hultgren SJ, Wyns L, Klemm P, Oscarson S, Knight SD, De Greve H.

Mol Microbiol. 2005 Jan;55(2):441-55.


Development of a recombinant FimCH vaccine for urinary tract infections.

Langermann S, Ballou WR.

Adv Exp Med Biol. 2003;539(Pt B):635-48. Review. No abstract available.


Fimch antiserum inhibits the adherence of Escherichia coli to cells collected by voided urine specimens of diabetic women.

Meiland R, Geerlings SE, Langermann S, Brouwer EC, Coenjaerts FE, Hoepelman AI.

J Urol. 2004 Apr;171(4):1589-93.


PC cell-derived growth factor expression in prostatic intraepithelial neoplasia and prostatic adenocarcinoma.

Pan CX, Kinch MS, Kiener PA, Langermann S, Serrero G, Sun L, Corvera J, Sweeney CJ, Li L, Zhang S, Baldridge LA, Jones TD, Koch MO, Ulbright TM, Eble JN, Cheng L.

Clin Cancer Res. 2004 Feb 15;10(4):1333-7.


Differential EphA2 epitope display on normal versus malignant cells.

Coffman KT, Hu M, Carles-Kinch K, Tice D, Donacki N, Munyon K, Kifle G, Woods R, Langermann S, Kiener PA, Kinch MS.

Cancer Res. 2003 Nov 15;63(22):7907-12.


Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences.

Dall'Acqua WF, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA, Wu H, Kiener PA, Langermann S.

J Immunol. 2002 Nov 1;169(9):5171-80.


Structural basis of tropism of Escherichia coli to the bladder during urinary tract infection.

Hung CS, Bouckaert J, Hung D, Pinkner J, Widberg C, DeFusco A, Auguste CG, Strouse R, Langermann S, Waksman G, Hultgren SJ.

Mol Microbiol. 2002 May;44(4):903-15.


[Candidate vaccine against urinary tract infections].

Hoepelman IM, Meiland R, Langermann S.

Ned Tijdschr Geneeskd. 2001 Sep 22;145(38):1860-2. Review. Dutch.


Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection.

Wizemann TM, Heinrichs JH, Adamou JE, Erwin AL, Kunsch C, Choi GH, Barash SC, Rosen CA, Masure HR, Tuomanen E, Gayle A, Brewah YA, Walsh W, Barren P, Lathigra R, Hanson M, Langermann S, Johnson S, Koenig S.

Infect Immun. 2001 Mar;69(3):1593-8.


Vaccination utilizing the FimCH complex as a strategy to prevent Escherichia coli urinary tract infections.

Langermann S, Ballou WR Jr.

J Infect Dis. 2001 Mar 1;183 Suppl 1:S84-6. Review. No abstract available.


Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis.

Adamou JE, Heinrichs JH, Erwin AL, Walsh W, Gayle T, Dormitzer M, Dagan R, Brewah YA, Barren P, Lathigra R, Langermann S, Koenig S, Johnson S.

Infect Immun. 2001 Feb;69(2):949-58.


PapD-like chaperones provide the missing information for folding of pilin proteins.

Barnhart MM, Pinkner JS, Soto GE, Sauer FG, Langermann S, Waksman G, Frieden C, Hultgren SJ.

Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7709-14.


Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli.

Langermann S, Möllby R, Burlein JE, Palaszynski SR, Auguste CG, DeFusco A, Strouse R, Schenerman MA, Hultgren SJ, Pinkner JS, Winberg J, Guldevall L, Söderhäll M, Ishikawa K, Normark S, Koenig S.

J Infect Dis. 2000 Feb;181(2):774-8.


Selective deletion of antigen-specific, activated T cells by a humanized MAB to CD2 (MEDI-507) is mediated by NK cells.

Branco L, Barren P, Mao SY, Pfarr D, Kaplan R, Postema C, Langermann S, Koenig S, Johnson S.

Transplantation. 1999 Nov 27;68(10):1588-96.


X-ray structure of the FimC-FimH chaperone-adhesin complex from uropathogenic Escherichia coli.

Choudhury D, Thompson A, Stojanoff V, Langermann S, Pinkner J, Hultgren SJ, Knight SD.

Science. 1999 Aug 13;285(5430):1061-6.


Adhesins as targets for vaccine development.

Wizemann TM, Adamou JE, Langermann S.

Emerg Infect Dis. 1999 May-Jun;5(3):395-403. Review.


Site-directed immunogenesis.

Langermann S.

Nat Med. 1998 May;4(5):547-8. No abstract available.


Systemic immunization with conserved pilus-associated adhesins protects against mucosal infections.

Palaszynski S, Pinkner J, Leath S, Barren P, Auguste CG, Burlein J, Hultgren S, Langermann S.

Dev Biol Stand. 1998;92:117-22.


Adherence of Streptococcus pneumoniae to human bronchial epithelial cells (BEAS-2B).

Adamou JE, Wizemann TM, Barren P, Langermann S.

Infect Immun. 1998 Feb;66(2):820-2.


Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination.

Langermann S, Palaszynski S, Barnhart M, Auguste G, Pinkner JS, Burlein J, Barren P, Koenig S, Leath S, Jones CH, Hultgren SJ.

Science. 1997 Apr 25;276(5312):607-11.


New approaches to mucosal immunization.

Langermann S.

Semin Gastrointest Dis. 1996 Jan;7(1):12-8. Review.


Efficacy and safety of live recombinant BCG vaccines.

Hanson MS, Bansal GP, Langermann S, Stover CK, Orme I.

Dev Biol Stand. 1995;84:229-36. Review.


Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi.

Langermann S, Palaszynski S, Sadziene A, Stover CK, Koenig S.

Nature. 1994 Dec 8;372(6506):552-5.


Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A.

Langermann S, Palaszynski SR, Burlein JE, Koenig S, Hanson MS, Briles DE, Stover CK.

J Exp Med. 1994 Dec 1;180(6):2277-86.


Molecular analysis of the Haemophilus influenzae type b pilin gene.

Langermann S, Wright A.

Mol Microbiol. 1990 Feb;4(2):221-30.


Pilus-mediated adherence of Escherichia coli K1 to human oral epithelial cells.

Clegg H, Guerina N, Langermann S, Kessler TW, Guerina V, Goldmann D.

Infect Immun. 1984 Jul;45(1):299-301.


The role of pili and capsule in the pathogenesis of neonatal infection with Escherichia coli K1.

Guerina NG, Kessler TW, Guerina VJ, Neutra MR, Clegg HW, Langermann S, Scannapieco FA, Goldmann DA.

J Infect Dis. 1983 Sep;148(3):395-405.


Adherence of piliated Haemophilus influenzae type b to human oropharyngeal cells.

Guerina NG, Langermann S, Clegg HW, Kessler TW, Goldman DA, Gilsdorf JR.

J Infect Dis. 1982 Oct;146(4):564. No abstract available.


Supplemental Content

Loading ...
Support Center